Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Sickle Cell Disease.

Saraf SL, Rondelli D.

J Clin Med. 2019 Oct 1;8(10). pii: E1565. doi: 10.3390/jcm8101565. Review.

2.

Kidney ultrasound findings according to kidney function in sickle cell anemia.

Patel R, Kang S, Valeshabad AK, Shah BN, Han J, Gowhari M, Molokie RE, Xie K, Lash JP, Gordeuk VR, Saraf SL.

Am J Hematol. 2019 Nov;94(11):E288-E291. doi: 10.1002/ajh.25602. Epub 2019 Aug 18. No abstract available.

PMID:
31379007
3.

The experience of adults with sickle cell disease and their HLA-matched adult sibling donors after allogeneic hematopoietic stem cell transplantation.

Gallo AM, Patil CL, Knafl KA, Angst DA, Rondelli D, Saraf SL.

J Adv Nurs. 2019 Jul 9. doi: 10.1111/jan.14152. [Epub ahead of print]

PMID:
31287187
4.

Laparoscopic Sleeve Gastrectomy in Sickle Cell Disease: a Case Series.

Han J, Gowhari M, Gordeuk VR, Saraf SL.

Obes Surg. 2019 Jun 10. doi: 10.1007/s11695-019-03983-5. [Epub ahead of print]

PMID:
31183783
5.

Type 2 diabetes in adults with sickle cell disease: can we dive deeper? Response to Skinner et al.

Zhou J, Han J, Nutescu EA, Galanter WL, Walton SM, Gordeuk VR, Saraf SL, Calip GS.

Br J Haematol. 2019 Sep;186(5):782-783. doi: 10.1111/bjh.15949. Epub 2019 May 8. No abstract available.

PMID:
31066029
6.

The morbidity and mortality of end stage renal disease in sickle cell disease.

Viner M, Zhou J, Allison D, Han J, Molokie RE, Jain S, Gowhari M, Gordeuk VR, Calip G, Saraf SL.

Am J Hematol. 2019 May;94(5):E138-E141. doi: 10.1002/ajh.25439. Epub 2019 Mar 1. No abstract available.

PMID:
30773675
7.

Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six-year population-based cohort analysis.

Zhou J, Han J, Nutescu EA, Galanter WL, Walton SM, Gordeuk VR, Saraf SL, Calip GS.

Br J Haematol. 2019 Apr;185(1):116-127. doi: 10.1111/bjh.15773. Epub 2019 Feb 3.

PMID:
30714090
8.

"Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia.

Akingbola TS, Tayo BO, Ezekekwu CA, Sonubi O, Zhang X, Saraf SL, Molokie R, Hsu LL, Han J, Cooper RS, Gordeuk VR.

Am J Hematol. 2019 Apr;94(4):E112-E115. doi: 10.1002/ajh.25412. Epub 2019 Feb 6. No abstract available.

PMID:
30663794
9.

Use of metformin in patients with sickle cell disease.

Han J, Saraf SL, Molokie RE, Gordeuk VR.

Am J Hematol. 2019 Jan;94(1):E13-E15. doi: 10.1002/ajh.25313. Epub 2018 Nov 9. No abstract available.

PMID:
30328140
10.

High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease.

Han J, Saraf SL, Gowhari M, Jain S, Molokie RE, Gordeuk VR.

Am J Hematol. 2019 Jan;94(1):E5-E7. doi: 10.1002/ajh.25311. Epub 2018 Oct 31. No abstract available.

PMID:
30299555
11.

HMOX1 and acute kidney injury in sickle cell anemia.

Saraf SL, Viner M, Rischall A, Raslan R, Shah BN, Zhang X, Han J, Gowhari M, Jain S, Molokie RE, Machado RF, Lash JP, Gordeuk VR.

Blood. 2018 Oct 11;132(15):1621-1625. doi: 10.1182/blood-2018-05-853929. Epub 2018 Aug 23. No abstract available.

12.

Hemolysis and hemolysis-related complications in females vs. males with sickle cell disease.

Raslan R, Shah BN, Zhang X, Kanias T, Han J, Machado RF, Gladwin MT, Gordeuk VR, Saraf SL.

Am J Hematol. 2018 Nov;93(11):E376-E380. doi: 10.1002/ajh.25258. Epub 2018 Oct 17. No abstract available.

PMID:
30117177
13.

Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.

Guilcher GMT, Truong TH, Saraf SL, Joseph JJ, Rondelli D, Hsieh MM.

Semin Hematol. 2018 Apr;55(2):87-93. doi: 10.1053/j.seminhematol.2018.04.011. Epub 2018 Apr 25. Review.

14.

Risk factors for vitamin D deficiency in sickle cell disease.

Han J, Zhang X, Saraf SL, Gowhari M, Molokie RE, Hassan J, Jain S, Shah BN, Abbasi T, Machado RF, Gordeuk VR.

Br J Haematol. 2018 Jun;181(6):828-835. doi: 10.1111/bjh.15270. Epub 2018 May 16.

15.

Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study.

Zhou J, Han J, Nutescu EA, Gordeuk VR, Saraf SL, Calip GS.

Br J Haematol. 2018 Jul;182(2):259-270. doi: 10.1111/bjh.15396. Epub 2018 May 16.

16.

Fixed Low-Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Anemia in Nigeria.

Tayo BO, Akingbola TS, Saraf SL, Shah BN, Ezekekwu CA, Sonubi O, Hsu LL, Cooper RS, Gordeuk VR.

Am J Hematol. 2018 May 14. doi: 10.1002/ajh.25143. [Epub ahead of print] No abstract available.

17.

Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease.

Saraf SL, Oh AL, Patel PR, Sweiss K, Koshy M, Campbell-Lee S, Gowhari M, Jain S, Peace D, Quigley JG, Khan I, Molokie RE, Mahmud N, Gordeuk VR, Rondelli D.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1759-1765. doi: 10.1016/j.bbmt.2018.03.031. Epub 2018 Apr 12.

18.

Red blood cell alloimmunization in sickle cell disease: assessment of transfusion protocols during two time periods.

Campbell-Lee SA, Gvozdjan K, Choi KM, Chen YF, Saraf SL, Hsu LL, Gordeuk VR, Strauss RG, Triulzi DJ.

Transfusion. 2018 Jul;58(7):1588-1596. doi: 10.1111/trf.14588. Epub 2018 Mar 23.

PMID:
29570817
19.

Progressive glomerular and tubular damage in sickle cell trait and sickle cell anemia mouse models.

Saraf SL, Sysol JR, Susma A, Setty S, Zhang X, Gudehithlu KP, Arruda JAL, Singh AK, Machado RF, Gordeuk VR.

Transl Res. 2018 Jul;197:1-11. doi: 10.1016/j.trsl.2018.01.007. Epub 2018 Feb 2.

20.

Urinary orosomucoid is associated with progressive chronic kidney disease stage in patients with sickle cell anemia.

Jerebtsova M, Saraf SL, Soni S, Afangbedji N, Lin X, Raslan R, Gordeuk VR, Nekhai S.

Am J Hematol. 2018 Aug;93(4):E107-E109. doi: 10.1002/ajh.25036. Epub 2018 Feb 5. No abstract available.

21.

Identification of ceruloplasmin as a biomarker of chronic kidney disease in urine of sickle cell disease patients by proteomic analysis.

Jerebtsova M, Saraf SL, Lin X, Lee G, Adjei EA, Kumari N, Afangbedji N, Raslan R, McLean C, Gordeuk VR, Nekhai S.

Am J Hematol. 2018 Feb;93(2):E45-E47. doi: 10.1002/ajh.24965. Epub 2017 Nov 27. No abstract available.

22.

A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma.

Patel P, Oh AL, Koshy M, Sweiss K, Saraf SL, Quigley JG, Khan I, Mahmud N, Hacker E, Ozer H, Peace DJ, Weichselbaum RR, Aydogan B, Rondelli D.

Leuk Lymphoma. 2018 Jul;59(7):1666-1671. doi: 10.1080/10428194.2017.1390231. Epub 2017 Oct 25.

PMID:
29065747
23.

Program expansion of a day hospital dedicated to manage sickle cell pain.

Han J, Saraf SL, Kavoliunaite L, Jain S, Hassan J, Hsu LL, Molokie RE, Gordeuk VR, Gowhari M.

Am J Hematol. 2018 Jan;93(1):E20-E21. doi: 10.1002/ajh.24938. Epub 2017 Oct 31. No abstract available.

24.

Associations of α-thalassemia and BCL11A with stroke in Nigerian, United States, and United Kingdom sickle cell anemia cohorts.

Saraf SL, Akingbola TS, Shah BN, Ezekekwu CA, Sonubi O, Zhang X, Hsu LL, Gladwin MT, Machado RF, Cooper RS, Gordeuk VR, Tayo BO.

Blood Adv. 2017 Apr 25;1(11):693-698. doi: 10.1182/bloodadvances.2017005231.

25.

Characterization of opioid use in sickle cell disease.

Han J, Zhou J, Saraf SL, Gordeuk VR, Calip GS.

Pharmacoepidemiol Drug Saf. 2018 May;27(5):479-486. doi: 10.1002/pds.4291. Epub 2017 Aug 16.

26.

Erythropoiesis-stimulating agents in sickle cell anaemia.

Han J, Zhou J, Kondragunta V, Zhang X, Molokie RE, Gowhari M, Hassan J, Jain S, Calip GS, Gordeuk VR, Saraf SL.

Br J Haematol. 2018 Aug;182(4):602-605. doi: 10.1111/bjh.14846. Epub 2017 Jul 27. No abstract available.

27.

Use of anti-inflammatory analgesics in sickle-cell disease.

Han J, Saraf SL, Lash JP, Gordeuk VR.

J Clin Pharm Ther. 2017 Oct;42(5):656-660. doi: 10.1111/jcpt.12592. Epub 2017 Jul 10.

28.

Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial.

Quinn CT, Saraf SL, Gordeuk VR, Fitzhugh CD, Creary SE, Bodas P, George A, Raj AB, Nero AC, Terrell CE, McCord L, Lane A, Ackerman HC, Yang Y, Niss O, Taylor MD, Devarajan P, Malik P.

Am J Hematol. 2017 Sep;92(9):E520-E528. doi: 10.1002/ajh.24810. Epub 2017 Jul 19.

29.

Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways.

Han J, Zhang X, Oderinde J, Saraf SL, Gowhari M, Hassan J, Jain S, Gordeuk VR, Molokie RE.

Haematologica. 2017 Aug;102(8):e282-e284. doi: 10.3324/haematol.2017.169128. Epub 2017 May 4. No abstract available.

30.

Association of circulating transcriptomic profiles with mortality in sickle cell disease.

Desai AA, Lei Z, Bahroos N, Maienschein-Cline M, Saraf SL, Zhang X, Shah BN, Nouraie SM, Abbasi T, Patel AR, Lang RM, Lussier Y, Garcia JGN, Gordeuk VR, Machado RF.

Blood. 2017 Jun 1;129(22):3009-3016. doi: 10.1182/blood-2016-11-752279. Epub 2017 Apr 3.

31.

A genetic variation associated with plasma erythropoietin and a non-coding transcript of PRKAR1A in sickle cell disease.

Zhang X, Shah BN, Zhang W, Saraf SL, Miasnikova G, Sergueeva A, Ammosova T, Niu X, Nouraie M, Nekhai S, Castro O, Gladwin MT, Prchal JT, Garcia JG, Machado RF, Gordeuk VR.

Hum Mol Genet. 2016 Oct 15;25(20):4601-4609. doi: 10.1093/hmg/ddw299.

32.

Reply to Ruan X et al: "A comment on pattern of opioid use in sickle cell disease".

Han J, Saraf SL, Machado RF, Gordeuk VR.

Am J Hematol. 2017 Apr;92(4):E43. doi: 10.1002/ajh.24646. Epub 2017 Feb 7. No abstract available.

33.

Patterns of opioid use in sickle cell disease.

Han J, Saraf SL, Zhang X, Gowhari M, Molokie RE, Hassan J, Alhandalous C, Jain S, Younge J, Abbasi T, Machado RF, Gordeuk VR.

Am J Hematol. 2016 Nov;91(11):1102-1106. doi: 10.1002/ajh.24498. Epub 2016 Aug 8.

34.

APOL1, α-thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia.

Saraf SL, Shah BN, Zhang X, Han J, Tayo BO, Abbasi T, Ostrower A, Guzman E, Molokie RE, Gowhari M, Hassan J, Jain S, Cooper RS, Machado RF, Lash JP, Gordeuk VR.

Haematologica. 2017 Jan;102(1):e1-e6. doi: 10.3324/haematol.2016.154153. Epub 2016 Sep 22. No abstract available.

35.

Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center.

Han J, Bhat S, Gowhari M, Gordeuk VR, Saraf SL.

Pharmacotherapy. 2016 Nov;36(11):1166-1172. doi: 10.1002/phar.1834. Epub 2016 Oct 3.

36.

Anion Effects in Oxidative Aliphatic Carbon-Carbon Bond Cleavage Reactions of Cu(II) Chlorodiketonate Complexes.

Saraf SL, Miłaczewska A, Borowski T, James CD, Tierney DL, Popova M, Arif AM, Berreau LM.

Inorg Chem. 2016 Jul 18;55(14):6916-28. doi: 10.1021/acs.inorgchem.6b00456. Epub 2016 Jul 5.

PMID:
27377103
37.

Safety of chronic transdermal fentanyl use in patients receiving hemodialysis.

Han J, Saraf SL, Gordeuk VR, Gowhari M.

Am J Health Syst Pharm. 2016 Jul 1;73(13):947-8. doi: 10.2146/ajhp150748. No abstract available.

38.

Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms.

Khan I, Shergill A, Saraf SL, Chen YF, Patel PR, Quigley JG, Peace D, Gordeuk VR, Hoffman R, Rondelli D.

Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):350-7. doi: 10.1016/j.clml.2016.02.036. Epub 2016 Mar 8.

PMID:
27052852
39.

Utility of the revised cardiac risk index for predicting postsurgical morbidity in Hb SC and Hb Sβ+-thalassemia sickle cell disease.

Rosenberg A, Selounski V, Wardak H, Han J, Gowhari M, Hassan J, Jain S, Molokie RE, Gordeuk VR, Saraf SL.

Am J Hematol. 2016 Jun;91(6):E316-7. doi: 10.1002/ajh.24363. Epub 2016 Apr 24. No abstract available.

40.

Conjunctival microvascular hemodynamics following vaso-occlusive crisis in sickle cell disease.

Kord Valeshabad A, Wanek J, Gaynes B, Saraf SL, Molokie R, Shahidi M.

Clin Hemorheol Microcirc. 2015 Sep 25;62(4):359-67. doi: 10.3233/CH-151977.

PMID:
26444608
41.

Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease.

Saraf SL, Oh AL, Patel PR, Jalundhwala Y, Sweiss K, Koshy M, Campbell-Lee S, Gowhari M, Hassan J, Peace D, Quigley JG, Khan I, Molokie RE, Hsu LL, Mahmud N, Levinson DJ, Pickard AS, Garcia JG, Gordeuk VR, Rondelli D.

Biol Blood Marrow Transplant. 2016 Mar;22(3):441-8. doi: 10.1016/j.bbmt.2015.08.036. Epub 2015 Sep 5.

42.

Changes in Conjunctival Hemodynamics Predict Albuminuria in Sickle Cell Nephropathy.

Kord Valeshabad A, Wanek J, Saraf SL, Gaynes BI, Gordeuk VR, Molokie RE, Shahidi M.

Am J Nephrol. 2015;41(6):487-93. doi: 10.1159/000438678. Epub 2015 Aug 5.

43.

Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy.

Saraf SL, Zhang X, Shah B, Kanias T, Gudehithlu KP, Kittles R, Machado RF, Arruda JA, Gladwin MT, Singh AK, Gordeuk VR.

Haematologica. 2015 Oct;100(10):1275-84. doi: 10.3324/haematol.2015.124875. Epub 2015 Jul 23.

44.

Genetic polymorphism of APOB is associated with diabetes mellitus in sickle cell disease.

Zhang X, Zhang W, Saraf SL, Nouraie M, Han J, Gowhari M, Hassan J, Miasnikova G, Sergueeva A, Nekhai S, Kittles R, Machado RF, Garcia JG, Gladwin MT, Steinberg MH, Sebastiani P, McClain DA, Gordeuk VR.

Hum Genet. 2015 Aug;134(8):895-904. doi: 10.1007/s00439-015-1572-3. Epub 2015 May 30.

45.

Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study.

Patel P, Aydogan B, Koshy M, Mahmud D, Oh A, Saraf SL, Quigley JG, Khan I, Sweiss K, Mahmud N, Peace DJ, DeMasi V, Awan AM, Weichselbaum RR, Rondelli D.

Biol Blood Marrow Transplant. 2014 Dec;20(12):2034-41. doi: 10.1016/j.bbmt.2014.09.005. Epub 2014 Sep 16.

46.

Hyperfiltration is associated with the development of microalbuminuria in patients with sickle cell anemia.

Vazquez B, Shah B, Zhang X, Lash JP, Gordeuk VR, Saraf SL.

Am J Hematol. 2014 Dec;89(12):1156-7. doi: 10.1002/ajh.23817. Epub 2014 Aug 27. No abstract available.

47.

Comparison of patients from Nigeria and the USA highlights modifiable risk factors for sickle cell anemia complications.

Akingbola TS, Tayo BO, Salako B, Layden JE, Hsu LL, Cooper RS, Gordeuk VR, Saraf SL.

Hemoglobin. 2014;38(4):236-43. doi: 10.3109/03630269.2014.927363. Epub 2014 Jun 18.

48.

Differences in the clinical and genotypic presentation of sickle cell disease around the world.

Saraf SL, Molokie RE, Nouraie M, Sable CA, Luchtman-Jones L, Ensing GJ, Campbell AD, Rana SR, Niu XM, Machado RF, Gladwin MT, Gordeuk VR.

Paediatr Respir Rev. 2014 Mar;15(1):4-12. doi: 10.1016/j.prrv.2013.11.003. Epub 2013 Nov 15. Review.

49.

Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia.

Saraf SL, Zhang X, Kanias T, Lash JP, Molokie RE, Oza B, Lai C, Rowe JH, Gowhari M, Hassan J, Desimone J, Machado RF, Gladwin MT, Little JA, Gordeuk VR.

Br J Haematol. 2014 Mar;164(5):729-39. doi: 10.1111/bjh.12690. Epub 2013 Dec 12.

50.

Improved outcomes with novel agents and auto-SCT for multiple myeloma in African-American patients.

Saraf SL, Patel P, Ozer H, Peace DJ, Quigley JG, Mahmud N, Rondelli D.

Bone Marrow Transplant. 2013 Feb;48(2):319-20. doi: 10.1038/bmt.2012.148. Epub 2012 Aug 6. No abstract available.

PMID:
22863727

Supplemental Content

Loading ...
Support Center